Differential proteins among normal cervix cells and cervical cancer cells with HPV-16 infection, through mass spectrometry-based Proteomics (2D-DIGE) in women from Southern México

Idanya Serafín-Higuera¹, Olga Lilia Garibay-Cerdenares², Berenice Illades-Aguiar², Eugenia Flores-Alfaro¹, Marco Antonio Jiménez-López³, Pavel Sierra-Martínez¹ and Luz del Carmen Alarcón-Romero¹⁴*
Background

Cervical cancer is the fourth most common malignancy and accounts for 10–15 % of cancer-related deaths in women worldwide [1, 2]. Cervical cancer affects approximately six out of 100,000 women and accounts for approximately 275,000 deaths annually in developing countries, which corresponds to 88 % of cases worldwide [2, 3].

Human papillomavirus (HPV) is the main etiological agent of cervical cancer detected in 95 to 100 % of cases [4–6]. Although more than 150 variants of this virus exist, only certain genotypes, such as HPV 16, 18, 33, 45 and 58 are known as high-risk types (HR-HPV); low-risk HPV types (LR-HPV), mainly HPV 6 and 11, seldom cause genital tumors; however, they do cause condylomata acuminata (anogenital warts) [7]. Persistent HPV oncoprotein expression (E6/E7) in HPV infected epithelial basal cells deregulates cell division [8]. Overexpression of these viral genes causes the deregulation of cell proliferation, metabolism, apoptosis, differentiation and genomic instability, all of which may lead to consecutive stages of cervical cancer [9].

Current approaches for the prevention of cervical cancer relies mainly on the cytologic screening, known as the Pap test, often combined with the detection of high-risk human papillomaviruses (HR-HPVs) [10]. Patients with abnormal Paps undergo colposcopy with directed biopsies. If precursor lesions are identified, patients are treated by cryotherapy or loop electrosurgical excision procedure (LEEP). The treatment is effective in the prevention of cervical cancer; however, it is expensive, cumbersome, and dependent on very good infrastructure and well-trained personnel [11]. Nevertheless, the diagnosis may results in a poor outcome, which lies on the lack of valuable objective indicators for determining cervical chronic inflammation, reactive hyperplasia, and benign or malignant lesions [12].

Compared with conventional 2-DE, two-dimensional differential in-gel electrophoresis (2D-DIGE)-based quantitative proteomics has several advantages, such as higher sensitivity, accuracy, and reproducibility, which facilitate spot-to-spot comparisons, precisely because of pre-labeling of protein samples with different fluorescent dyes (Cy3, and Cy5) prior to separation by 2-DE [13]. As a result, samples labeled with different dyes are separated in the same 2D gel; moreover, the same internal standard is used in all gels to avoid inter-gel variation [12, 14]. In the present study, a differential proteomic technique was applied for the comparative analysis of cervical cancer samples infected with HPV 16 and normal cervical tissue.

Results

To carry out a comparative analysis of cervical cancer/HPV-16 and normal samples without HPV, a proteomic analysis was done. Two groups of pooled samples were used. The first one consisted of six samples from women (average age of 50.7 years) diagnosed with HPV-16, by the INNOLIPA assay, and with histopathological staging of squamous cell carcinoma (SCC) of which four cases were stage IIB, one stage IB1 and one case stage IB2. The second group consisted of four pooled samples from women (mean age of 49.8 years) with normal cytology and colposcopy and negative for HPV infection. In Fig. 1 is observed the proliferation index of the cervical tissues by immunohistochemistry. Figure 2 shows the protein profile of each pooled sample, used as a reference pattern, allowing the visualization of more than 2204 spots that were resolved for each 2D gel analyzed. The samples were pooled in two groups and analyzed by triplicated and whose profiles showed technical reproducibility.

To compare samples, Decyder software (www.gelifesciences.com) was used, which is a platform that allows the qualitative and quantitative evaluation of spots profiles from fluorescent bidimensional electrophoresis gels (DIGE) (Fig. 3).

**Fig. 1** Expression of Ki-67. **a** Without SIL and HPV infection tissue showing nuclear immunostaining was exclusively confined to the parabasal layers of normal epithelium **b** SCC and HPV-16 infection tissue showing strong immunostaining of Ki-67 in large pleomorphic nuclei of malignant squamous cells form irregular nests invading the stroma. 40 X Immunohistochemistry
The profile of proteins achieved under these conditions was reproducible among pools, the comparison showed different areas of differential expression (yellow spots). An area with a differential expression pattern among samples was located, from which 129 spots with a diminishing expression and 150 with increased expression $\pm$ 5 times, 53 spots showed a greater differential expression and the identification of the ten spots was achieved by Mass Spectrometry (MALDI-TOF). Figure 4 shows that Mimecan, Actin aortic smooth muscle and Lumican increased their expression in cervical cancer, in comparison with normal cervical cells, while Keratin, type II cytoskeletal 5, Peroxiredoxin-1 and 14-3-3 protein sigma showed a decrease in their protein expression pattern in cervical cancer in comparison with no SIL tissues.

Table 1 shows the identification of proteins and some biochemical characteristics as name, identification code, and chromosomal localization among others.

Analyzing the participation of the identified proteins in different cellular pathways through Reactome Database (www.reactome.org), the results suggest biosynthesis, metabolism and degradation of keratan sulfate, transcriptional regulation by TP53, metabolism of carbohydrates, intrinsic pathway for apoptosis, detoxification of reactive oxygen species, and cell cycle as the most important.

**Discussion**

In 2012 the CC was the second cause of cancer death in Mexican women [15], HPV-16 has been reported in studies carried out by our group, as the more common in populations of women of the southern region of Mexico since 1997 [16, 17].

Multiple genes are involved in the occurrence and development of cancers, and even tough genes carry the genetic information, proteins are the final executors of life events [1]. Due to this, the proteomic profiling offers
Fig. 4 Comparison of protein expression levels among normal cervical cells without HPV infection, and cervical cancer HPV16 infection groups. Decyder software allowed the tridimensional comparisons between study groups.
an option for the selection of differential protein patterns whose expression levels could be associated with progression, prognosis and/or survival.

There have been several experimental approaches for the analysis of differential protein expression in cervical cancer, such as the analysis of tissues [12], cells [1], and even plasma samples [12]. In this study, cells that come from women with cervical cancer and infection with HPV-16 were compared with normal cells of the cervix recovered from individuals without HPV infection, diagnosed through INNOLIPA assay and in situ hybridization with tyramide amplification.

Bidimensional electrophoresis is a very useful tool to analyze broad and complex samples, through the wide distribution of protein profiles based on their isoelectric points and molecular weights. The additional use of fluorescence during this technique allows for an increase in sensitivity in 2D DIGE, and the use of special software facilitates the differential analysis. Finally, the use of MALDI-TOF MS, allowed the successful identification of ten differentially expressed proteins among the two different groups.

In the present study, the proteins identified were mimecan (osteoglycin), aortic smooth muscle, Lumican, Peroxiredoxin-1, 14-3-3 protein sigma, Alpha-enolase, Keratin, type II cytoskeletal 5, as differential proteins among cervical cancer and normal cervical cells, whose expression patterns were either increased or diminished. Mimecan (or Osteoglycin, OGN), is a secretory protein that belongs to a family of small leucine rich proteoglycans (SLRPs). It has been found in several cancer cell lines, although its physiological function has not been completely understood [18, 19], being abundant in bone matrix, cartilage cells, and connective tissues; it is also recognized as a promotor for cancer development [29]. The actin cytoskeleton is substantially altered in cancer cells as a result of the changes in the abundance of proteins, among other factors. As a result, cancer cells acquire increased motility and distinctive mechanical properties, which are important for processes such as invasion and metastasis [22]. ACTA2 is a α-smooth muscle actin whose expression is transformation sensitive to growth signals in normal cells [23].

In cases of basal cell carcinoma skin cancer, it has been found with a high expression too, both in the tumor and in the adjacent stroma and it is used as a marker of aggressiveness in pancreatic cancer, because it is presenting more aggressive histological variants [24], suggesting that the increased expression may contribute to the local invasion. It’s role in the biology of the tumor is not completely known, however, it has been hypothesized that increases in the cellular motility result in an increase in the cells capacity of invasion [25].

Lumican is a keratin sulphate belonging to the SLRP family of extracellular matrix (ECM) proteins and is expressed in different forms in several tissues and organs, such as cornea, bone, cartilage, artery, skin, kidney, and lung. It has been found to have a key role both in the organization of the extracellular matrix (ECM) and as an important modulator of biological functions in breast, lung, and pancreas cancer [26, 27], and it has been correlated with lung cancer progression as well [28].

The peroxiredoxins were identified primarily by their ability to protect the protein oxidative damage induced by free radicals, such as reactive oxygen species (ROS) and reactive nitrogen species (RNS), which is currently recognized as a promoter for cancer development [29]. The peroxiredoxins (Prdxs) are small proteins of sweep (scavenging) of H₂O₂, that could prevent tumor development since the loss of Prdx1 in mice leads to premature death due to cancer [30].

Keratins are expressed in all types of epithelial cells (simple, stratified, keratinized and cornified), are important protectors of epithelial structural integrity under

| Table 1 Differential expression of proteins in SCC/HPV-16 against control (without SIL and HPV infection) |
|-----------------------------------------------|----------------|----------------|----------------|----------------|
| Protein                               | Expression index (n+/−) | Accession number | Chromosomal localization | Gene | Peptide coverage (%) | Score |
|-----------------------------------------------|----------------|----------------|----------------|----------------|
| Mimecan                                | 38.85          | MINE_HUMAN     | 9q22            | OGN   | 46               | 956   |
| Mimecan                                | 31.23          | MINE_HUMAN     | 9q22            | OGN   | 54               | 820   |
| Actin, aortic smooth muscle             | 19.14          | ACTA_HUMAN     | 10q23.31        | ACTA2 | 59               | 311   |
| Mimecan                                | 17.77          | MINE_HUMAN     | 9q22            | OGN   | 54               | 447   |
| Lumican                                | 16.52          | LUM_HUMAN      | 12q21.33        | LUM   | 40               | 556   |
| Peroxiredoxin-1                        | –8.37          | PRDX1_HUMAN    | 1p34.1          | PRDX1 | 79               | 968   |
| 14-3-3 protein sigma                   | –14.97         | I433S_HUMAN    | 1p36.11         | SFN   | 67               | 977   |
| Alpha-enolase                          | –17.38         | ENOA_HUMAN     | 1p36.2          | ENO1  | 71               | 976   |
| Keratin, type II cytoskeletal 5        | –39.7          | K2CS_HUMAN     | 12q13.13        | KRTS  | 52               | 885   |
| Keratin, type II cytoskeletal 5        | –65.34         | K2CS_HUMAN     | 12q13.13        | KRTS  | 52               | 1 090 |
conditions of stress, but have also been recognized as regulators of other cellular functions, including motility, signaling, growth and protein synthesis [31]. KRT5 Keratin, type II cytoskeletal 5 was found decreased in primary early-stage cervical squamous cell cancer tissue with pelvic lymph node metastasis (PLNM) vs without PLNM using DIGE-based proteomics [32].

**Conclusion**

Based on the above results, it was possible to identify differential protein patterns among cases of cervical lesions related to cervical cancer progression with HPV-16 infection in comparison with tissue without lesion and negative for HPV infection from Mexican women. These proteins could be analyzed as potential candidates for biomarkers due to their relationship with their presence in early stages of cervical cancer development, improving the understanding of viral pathogenesis and its role in the development of cervical cancer. Eventually this information could be used in the development of strategies in clinical management, diagnosis and treatment.

**Methods**

**Study population**

A cross-sectional study was conducted, which included two study groups, the first included a pool of 6 cases of cervical cancer with HPV-16 infection (cervical cancer/HPV-16) of which four cases were stage IIB, one stage IB1 and one case stage IB2 and the second group, which served as a comparison, consisted of a pool of four cases from surgical specimens extracted by fibroids without lesions related to cervical cancer and without HPV infection, and whose previous cytological study showed normal cells with reactive changes to nonspecific inflammatory processes, with normal colposcopy. All cases had antecedents cytological that were reported according to the Bethesda System 2001 and without coninfection by *Trichomonas vaginalis*, *Candida sp*, *Actinomyces sp* and *Herpes simplex virus* [33].

The diagnosis and detection of HPV in each sample was performed as follows: three different sections of each biopsy were obtained. The first embedded in paraffin and were cut to a thickness of 3 μm (one stained with hematoxylin-eosin for histopathological diagnosis, another for detecting cell proliferation antigen Ki-67 and finally another slide for detection of DNA detection HPV by in situ hybridization with tyramid amplification). The second section was used for detection of HPV DNA by molecular analysis (INNOLIPA, Uniparts Innogenetics) and the third was used for protein extraction. These data allowed the formation of the two comparative groups (Table 2).

The cervical cancer tissues were obtained from the Instituto Estatal de Cancerología “Arturo Beltrán Ortega”, and normal cervix tissues from patients from the Hospital General “Dr. Jorge Soberón Acevedo”. The histopathological diagnosis was carried out by pathologists in each institution independently, according to each clinical record. Both groups contained women with no history of prior local treatment, chronic degenerative diseases, non-smoking and non-alcoholism history, and without coinfections corroborated by colposcopic, cytological and microbiological analyses. The diagnosis was reported in accordance with the system of the International Federation of Gynecology and Obstetrics (FIGO) [34]. Ages in both groups were 37–69 years with a mean age of 50.7 years among cervical cancer patients and 49.8 among patients free-cervical. Women signed an informed consent and their data were analyzed in a confidential manner. This study was approved by the Committee of Bioethics at the Autonomous University of Guerrero, Mexico, according to the ethical guidelines of the Declaration of Helsinki 2008 [35].

**Table 2** Characteristics of cervical tissues samples of comparatives groups CC/HPV-16 and control without SIL and HPV infection

| Tests | Pool CC/HPV-16 | Pool without SIL and HPV infection (control) |
|-------|----------------|---------------------------------------------|
| Background | Cytological study: Squamous cell carcinoma | Cytological study: normal cells with reactive changes to nonspecific inflammatory processes |
| | Colposcopic examination: cervical carcinoma | Normal colposcopy |
| | Clinical diagnosis: 4 cases stage IIB, one stage IB1 and 1 case stage IB2 | |
| Section 1 (paraffin embedding) | Squamous Cell Carcinoma | Negative |
| - Histopathological diagnosis (H-E) | Positive of HR-HPV | Negative |
| - in situ hybridization with tyramid amplification | Positive in large pleomorphic nuclei of malignant squamous cells form irregular nests invading the stroma | Positive in nuclei of parabasal cells in basal layer |
| - Immunohistochemistry for Ki-67 | HPV-16 | Negative of HPV infection |
| Section 2 | HPV-16 | |
| - INNO-LIPA extra (Genotyping of HVP) | Increased expression in cervical cancer Mimecan, Actin from aortic smooth muscle and Lumican. | Decreased expression: Keratin, type II cytoskeletal 5, Peroxiredoxin-1 and 14-3-3 protein sigma |
| Section 3 | | |

*Each sample of tissue fragment into three sections and all tests were performed, six samples for group CC / HPV-16 and four samples were used for the control group. For more details see section Methods

* Without coninfection by *Trichomonas vaginalis*, *Candida sp*, *Actinomyces sp*, *Herpes simplex virus* according to the Bethesda 2001 system
Immunohistochemistry for Ki-67
To evaluate the expression of Ki-67, the monoclonal antibody MIB-1 (Dako, Carpinteria, CA, USA) was used with the Cytoscan HRP/DAB immunohistochemical system of detection (Cell Marque Corporation, Hot Springs, AR, USA [now relocated to Rocklin, CA, USA]). The histological slices were deparaffinized and placed in a solution of immunoDNA Retriever (BioSB, Inc., Santa Barbara, CA, USA). For HVP-INNO-LIPA extra, the primary antibody, previously subjected to hybridization for 20 h (Hybridizer Dako, Carpinteria, CA, USA), a drop of test reagent (biotinylated viral DNA) with probes for 13 HR-HPV genotypes (16,18,31,33,39,45,51,52,56,58,59 and 68) was added to each slide. The slide were denatured for 10 min and subjected to hybridization for 20 h (Hybridizer Dako, Carpinteria, CA, USA). For HVP-INNO-LIPA extra, the DNA extraction from cervical tissue samples the conventional TRIZOL method (Cat. No.15596018, Invitrogen a part of life Tech. Corp) was used, according to the manufacturer’s instructions. Tissues were tested for the presence of the HPV genotypes by polymerase chain reaction (PCR), using the short PCR fragment 10 (SPF10) primers, a highly sensitive method for HPV DNA detection, according to the method of Pirog et al. [36].

Detection and genotyping of HPV DNA by in situ hybridization with tyramide amplification and INNO-LiPA Extra
In the in situ hybridization with a system of tyramide signal amplification (Gen Point Dako Cytomation, Carpinteria, CA, USA), a drop of test reagent (biotinylated viral DNA) with probes for 13 HR-HPV genotypes (16,18,31,33,39,45,51,52,56,58,59 and 68) was added to each slide. The slide were denatured for 10 min and subjected to hybridization for 20 h (Hybridizer Dako, Carpinteria, CA, USA). For HVP-INNO-LIPA extra, the DNA extraction from cervical tissue samples the conventional TRIZOL method (Cat. No.15596018, Invitrogen a part of life Tech. Corp) was used, according to the manufacturer’s instructions. Tissues were tested for the presence of the HPV genotypes by polymerase chain reaction (PCR), using the short PCR fragment 10 (SPF10) primers, a highly sensitive method for HPV DNA detection, according to the method of Pirog et al. [36].

Protein sample labeling with CyDye
CyDye DIGE fluoros (Cy2, Cy3, and Cy5) were used to label the protein extracts following the manufacturer’s protocol (GE Healthcare). The internal standard pool was generated by combining equal amounts of extracts from all samples, labeled with Cy2. Protein extracts from the normal and cervical cancer cells were labeled with Cy3 and Cy5, respectively. The labeling reaction was performed on ice for 30 min in darkness, and was then quenched with 10 mM llysine for 10 min on ice under dark conditions. The labeled samples were then mixed and prepared for the following steps.

2-D electrophoresis in polyacrylamide gel electrophoresis (SDS-PAGE)
Total extracts from normal and cancer tissues were processed according to Klose protocol [37]. Briefly, samples were diluted in rehydration buffer containing 8 M urea, 0.5 % (w/v) CHAPS, 10 mM DTT, 0.001 % bromophenol blue, and Bio-Lyte 3–10 Ampholyte (0.2 %) (Bio-Rad, Cat. No.163-1113). The protein mixture was then applied to ReadyStrip™ IPG 7 cm strips, pH 3–10 (linear). Rehydrated strips were isoelectrically focused using a PROTEAN IEF cell System. To perform the second dimension analysis, the strips were processed by 10 % SDS-PAGE. Finally the 2D gels were stained with Coomassie staining. The IPG strips were balanced in a buffer consisting of 1.5 M Tris–HCl pH 8.8, 6 M urea and 30 % v/v glycerol, 2 % p/v SDS and traces of bromophenol blue, being carried out in two steps, using in each 5 ml of balanced solution per strip; in the first one, the strips were incubated in the balanced buffer described above with 1 % w/v of DTT, remaining in this solution for 20 min in agitation at room temperature. In the second step, 2.5 % w/v of iodoacetamide was added to the balanced buffer, repeating the 20 min incubation in agitation at room temperature; once the procedure was completed, the proteins could be picked for mass spectrometry analysis.

Image analysis
The images were analyzed using the DeCyder™ 2D Differential Analysis Software (DeCyder 2D V8.0) by differential in-gel analysis (DIA) and biological variation analysis (BVA). Protein spots were marked and selected with changes in abundance ratio >1.5-fold, P values <0.05 for protein identification. The gels were subjected to Coomassie blue staining for spot visualization and picking.

Protein identification by MALDI-TOF
Coomassie-stained 2D gels were scanned and digital images were compared using the Decyder Software. Each pool was run three times. The electrophoreotic entities of interest were excised, alkylated, reduced, and digested up to obtain a peptide mass fingerprint. Peak lists of the tryptic peptide masses were generated using FlexAnalysis1.2xSD1 Patch 2 (Bruker Daltonics). The search engine MASCOT server 2.0 was used to compare the fingerprints against human taxonomy with the following parameters: one missed cleavage allowed, carbamidomethyl cysteine as the fixed modification and oxidation of methionine as the variable modification. Proteins with scores greater than 50 and a p < 0.05 were accepted.
Acknowledgments
We thank the strengthening program graduate high with file number: 1010/455/2013 C- 677/2013 of UAgro. Serafin-Higuera I was recipient of a Doctoral fellowship with file number 222252 from CONACYT, Mexico. We are grateful to Vladimir Rodrigo-Sandoval, Pathologist of Hospital General “Jorge Soberón Acevedo” Iguala, Guerrero, Mexico for help us in diagnosis support and to Dra Patricia Talamás-Rohana for manuscript review and comments.

Funding
This project was funded by Programa de Fortalecimiento Académico del Posgrado de Alta Calidad (1010/455/2013 C-677/2013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Authors' contributions
The work presented here was carried out in collaboration between all authors. Conceived and designed the experiments: ISH, LCAR. Analyzed the data: ISH, LCAR, BIA, EFA, PSM, OLGC. Contributed reagents/materials/analysis tools: ISH, LCAR, BIA, EFA, PSM, OLGC, MAIJ. Performed the experiments: ISH, LCAR. Analyzed the data: ISH, LCAR, BIA, EFA, PSM, OLGC. Wrote the paper: ISH, OLGC, LCAR. All authors read and approved the final manuscript.

Authors’ information
Olga Lilia Garibay-Cerdenares: Professor of CONACyT.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Informed consent was obtained from the patient for publication of this Ethinics approval and consent to participate Not applicable.

Authors
MAJL. Performed the experiments: ISH, LCAR. Analyzed the data: ISH, LCAR, BIA, EFA, PSM, OLGC. Contributed reagents/materials/analysis tools: ISH, LCAR, BIA, EFA, PSM, OLGC, MAIJ. Performed the experiments: ISH, LCAR. Analyzed the data: ISH, LCAR, BIA, EFA, PSM, OLGC. Wrote the paper: ISH, OLGC, LCAR. All authors read and approved the final manuscript.

Authors’ information
Olga Lilia Garibay-Cerdenares: Professor of CONACyT.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Informed consent was obtained from the patient for publication of this paper and this study was approved by the Committee of Bioethics at the Autonomous University of Guerrero, Mexico. Folio CB-002/16.

Author details
1. Laboratorio de Citopatología e Histoquímica, Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, México. 2. Laboratorio de Biomedicina Molecular, Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, México. 3. Instituto Estatal de Cancerología de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Avenida Lázaro Cárdenas, Ciudad Universitaria, Chilpancingo, Guerrero, C.P. 39000, México.

Received: 19 December 2015 Accepted: 16 August 2016
Published online: 05 September 2016

References
1. Zhao Q, He Y, Yang X, Zhang X, Guo W, Wu Y. Differentially expressed proteins among normal cervix, cervical intraepithelial neoplasia and cervical squamous cell carcinoma. Clin Transl Oncol. 2015;17:620–31.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5–29.
3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide. IARC Cancer Base No. 11. Lyon: International Agency for Research on Cancer, 2014. http://globocan.iarc.fr accessed on 5 Sep 2015.
4. Adam ML, Piri C, Tullio S, Cantalice JCL, Torres RA, Cornea MTDS. Assessment of the Association Between Micronuclei and the Degree of Uterine Lesions and Viral Load in Women with Human Papillomavirus. Cancer Genomics Proteomics. 2015;12:67–72.
5. Cortés-Gutiérrez EJ, Dávila-Rodríguez M, Vargas-Villarreal J, Hernández-Garza F, Cerda-Flores RM. Association between Human Papilloma Virus-type Infections with Micronuclei Frequencies. Prague Med Rep. 2010;111(1):35–41.
6. Snijders PIF, Steenbergen RDM, Heideman DAM, Meijer CJLM. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006;208:152–64.
7. Paavonen J. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int J Infect Dis. 2007; 11(Supplement 2):53–9.
8. Maglennon GA, McIntosh P, Doorbar J. Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology. 2011;414:153–63.
9. Van Raemdonck GAA, Tjafla WAA, Coen EP, Depuydt CE, Van Ostade XWM. Identification of Protein Biomarkers for Cervical Cancer Using Human Cervicovaginal Fluid. PLoS One. 2014;9:e106488.
10. Lyngø E, Rygaard C, Ballet MV-P, Dugue P-A, Sander BB, Bonde J, Reboll J. Cervical cancer screening at crossroads. APMS. 2014;122:667–73.
11. Kim HS. Correction: primary, secondary, and tertiary prevention of cervical cancer. J Gynecol Oncol. 2014;25:261.
12. Guo X, Hao Y, Kamilijiang M, Hasim A, Yuan J, Wu G, Reyimu H, Kadeer N, Abudula A. Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and Ingenuity Pathway Analysis. Tumor Biol. 2015;36:1711–20.
13. Mauya P, Mealey P, Dowling P, Clynes M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 2007;27(3A):1247–55.
14. Pressey JG, Pressey CS, Robinson G, Herring R, Wilson L, Kelly DR, Kim H. 2-D Difference Gel Electrophoretic Proteomic Analysis of a Cell Culture Model of Alveolar Rhabdomyosarcoma. J Proteome Res. 2011;10:624–36.
15. Gutiérrez JP, Rivera-Dommurro J, Sharmah-Levy T, Villalpando-Hernández S, Franco A, Cueva-Nasu L, et al. Encuesta Nacional de Salud y Nutrición 2012, Resultados Nacionales. Cuernavaca: Instituto Nacional de Salud Pública; 2012.
16. Ortiz-Ortiz J, Alarcon-Romo LM, Jimenez-Lopez M, Garzon-Barrientos V, Calleja-Macias J, Barrera-Saldana H, Leyva-Vázquez M, Illades-Aguilar B. Association of human papillomavirus 16 E6 variants with cervical carcinoma and precursor lesions in women from Southern Mexico. Viral J. 2015;12:29.
17. Illades-Aguilar B, Alarcón-Romo LG, Antonio-Tejar V, Zamudio-López N, Sales-Linares N, Flores-Affro E, Fernández-Tilapa G, Vences-Velázquez A, Muñoz-Valle J, Leyva-Vázquez M. Prevalence and distribution of human papillomavirus types in cervical cancer, squamous intraepithelial lesions, and with no intraepithelial lesions in women from Southern Mexico. Gynecol Oncol. 2010;10(17):291–6.
18. Yinghong W, Yu H, Bingjian L, Enping X, Qiong H, Maode L. Differential expression of mimecan and thiodexin domain-containing protein 5 in colorectal adenoma and cancer: a proteomic study. Exp Biomed Res. 2007; 232:1152–9.
19. Li L, Zhang Z, Wang C, Mao L, Zhang J, Wang J, Jiao B, Zhao S. Quantitative Proteomics Approach to Screening of Potential Diagnostic and Therapeutic Targets for Lanyngeal Carcinoma. PLoS One. 2014;9:e90181.
20. Zheng C, Zhao S, Wang P, Yu H, Wang C, Han B, Su B, Xiang Y, Li X, Li S, et al. Different expression of mimecan as a marker for differential diagnosis between NSCLC and SCL. Oncol Rep. 2009;22:1057–61.
21. Wang Y, Ma Y, Liu B, Xu E, Huang Q, Lai M. Differential expression of mimecan and thiodexin domain-containing protein 5 in colorectal adenoma and cancer: a proteomic study. Exp Biol Med. 2007;232:1152–9.
22. Efremov YM, Dokrunova AA, Efremenko AV, Kirpichnikov MD, Shaitan KV, Sokolova GS. Distinct impact of targeted actin cytoskeleton reorganization on mechanical properties of normal and malignant cells. Biochim Biophys. Acta. 2015;1853:1117–25.
23. Huang H-L, Yao H-S, Wang Y, Wang W-J, Hu Z-Q, Jin K-Z. Proteomic identification of tumor biomarkers associated with primary gallbladder cancer. World J Gastroenterol. 2014;20:5511–8.
24. Sinn M, Denkert C, Streller JK, Pelzer U, Steeler JM, Bahna M, Lohnies P, Dorken B, Oettle H, Riess H, Sinn BV. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br J Cancer. 2014;111:1917–23.
25. Mercut R, Cirea ME, Margaritescu C, Popenescu SM, Craitoiu MM, Cotoi OS, Voinescu DC. Expression of p53, D2-40 and a-smooth muscle actin expression and desmoplasmic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br J Cancer. 2014;111:1917–23.
26. Dohnhoff M, Morin J, Roughley PJ, Ludwig MS. Expression of Luminic in Human Lungs. Am J Respir Cell Mol Biol. 1998;19:582–7.
27. Niktovic D, Papoutsidakis A, Karamanos NK, Tzanakakis GN. Luminic affects cell proliferation and early apoptosis of colorectal adenocarcinoma cells. J Cell Sci. 2014;127:2559–68.
28. Cappellesso R, Millioni R, Arrigoni G, Simonato F, Caroccia B, Iori E, Guzzardo V, Ventura L, Tesari P, Fassina A. Lumican Is Overexpressed in Lung Adenocarcinoma Pleural Effusions. PLoS One. 2015;10:e0126458.
29. Rhee SG, Woo HA, Kil IS, Bae SH. Peroxiredoxin Functions as a Peroxidase and a Regulator and Sensor of Local Peroxides. J Biol Chem. 2012;287:4403–10.
30. Neumann CA, Fang Q. Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol. 2007;7:375–80.
31. Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2011;30(2):127–38.
32. Wang W, Xia H-L, Huang J-M, Liang Y-C, Tan H, Geng H-Z, et al. Identification of biomarkers for lymph node metastasis in early-stage cervical cancer by tissue-based proteomics. Br J Cancer. 2014;110:1748–58.
33. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright Jr T, Young N. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet. 2000;70:209–62.
34. Benedet JL, Bender H, Jones III H, Ngan HYS, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet. 2000;70:209–62.
35. Williams JR. The Declaration of Helsinki and public health. Bull World Health Organ. 2008;86:502–2.
36. Pirog EC, Kleter B, Olcay S, Bobkiewicz P, Lindeman J, Quint WGV, et al. Prevalence of Human Papillomavirus DNA in Different Histological Subtypes of Cervical Adenocarcinoma. Am J Pathol. 2000;157:1055–62.
37. Klose J, Kobalz U. Two-dimensional electrophoresis of proteins: An updated protocol and implications for a functional analysis of the genome. Electrophoresis. 1995;16:1034–59.